Recurrent Herpes Labialis in Adults: New Tricks for an Old Dog

March 2017 | Volume 16 | Issue 3 | Supplement Individual Articles | 49 | Copyright © March 2017


Ted Rosen MD

Baylor College of Medicine, Houston, TX

REFERENCES

  1. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: A global review. J Infect Dis. 2002;186(suppl1):S3–S28.
  2. Xu F, Sternberg MR, Kottiri BJ, et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA. 2006;296:964-73.
  3. Spruance SL, Kriesel JD. Treatment of herpes simplex labialis. Herpes. 2002;9:64-9.
  4. Logan HL, Lutgendorf S, Hartwig A, et al. Immune, stress, and mood markers related to recurrent oral herpes outbreaks. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;86:48-54.
  5. Embil JA, Stephens RG, Manuel FR. Prevalence of recurrent herpes labialis and aphthous ulcers among young adults on six continents. Can Med Assoc J. 1975;113:627-30.
  6. Nikkels AF, Pièrard GE. Treatment of mucocutaneous presentations of herpes simplex virus infections. Am J Clin Dermatol. 2002;3:475-87.
  7. Fatahzadeh M1, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J Am Acad Dermatol. 2007;57:737-63.
  8. Yeung-Yue KA, Brentjens MH, Lee PC, et al. Herpes simplex viruses 1 and 2. Dermatol Clin.2002;20:249-66.
  9. Wolf R, Wolf D, Ruocco V. The benefits of smoking in skin diseases. Clin Dermatol. 1998;16:641-7.
  10. Donigan J, Pascoe V, Kimball A. Psoriasis and herpes simplex virus are highly stigmatizing compared with other common dermatologic conditions: A survey-based study. J Am Acad Dermatol. 2015;73:525-526.
  11. Ramchandani M, Kong M, Tronstein E, et al. Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults. Sex Transm Dis. 2016;43:756-760.
  12. Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections: an evidence-based review. Arch Intern Med. 2008;168:1137-44.
  13. Rahimi H, Mara T, Costella J. Effectiveness of antiviral agents for the prevention of recurrent herpes labialis: a systematic review and meta-analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;113:618-27.
  14. Chi CC, Wang SH, Delamere FM, et al. Interventions for prevention of herpes simplex labialis (cold sores on the lips). Cochrane Database Syst Rev. 2015 Aug 7;(8):CD010095.
  15. Bernstein DI, Spruance SL, Arora SS, et al. Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. Clin Infect Dis. 2005;41:808-14.
  16. Tsambaos D, Rodi M, Pasmatzi E, et al. Long-term remission of recurrent herpes labialis following topical imiquimod application on distant healthy skin: a clinical and immunological study. Antivir Ther. 2011;16:863-9.
  17. Hull CM, Harmenberg J, Arlander E, et al. Early treatment of cold sores with topical ME-609 decreases the frequency of ulcerative lesions: a randomized, double-blind, placebo-controlled, patient-initiated clinical trial. J Am Acad Dermatol. 2011;64:696.e1-11.
  18. Hull CM, McKeough M, Sebastian K, et al. Valacyclovir and topical clobetasol gel for the episodic treatment of herpes labialis: a patient-initiated, double-blind, placebo-controlled pilot trial. J Eur Acad Dermatol Venereol. 2009;23:263-67.
  19. Spruance SL, McKeough MB. Combination treatment with famciclovir and a topical corticosteroid gel versus famciclovir alone for experimental ultraviolet radiation-induced herpes simplex labialis: a pilot study J Infect Dis. 2000;181:1906-10.
  20. Yarlagadda SG, Perazella MA. Drug-induced crystal nephropathy: an update. Expert Opin Drug Saf . 2008;7:147–158.
  21. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45:804–817.
  22. Lam NN, Weir MA, Yao Z, et al. Risk of acute kidney injury from oral acyclovir: a population-based study. Am J Kidney Dis. 2013;61:723–729.
  23. Bieber T, Chosidow O, Bodsworth N, et al. Efficacy and safety of acyclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP Trial): A double-blind, placebo-controlled, self-initiated trial. J Drugs Dermatol. 2014;13:791-798.
  24. Rosen T. Pragmatic and Profound Benefits of Acyclovir Buccal Adhesive Tablets.J Drugs Dermatol. 2016;15:775-7.
  25. Lemarchand C, Singlas E, Costantini D, et al. Plasma, saliva and labial mucosa pharmacokinetics and pharmacodynamics of acyclovir Lauriad® mucoadhesive buccal tablet in healthy volunteers. J Clin Pharmacol Clin Pharmacokin. 2014;1 (1).
  26. Glenny AM, Fernandez Mauleffinch LM, Pavitt S, et al. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006706.
  27. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother. 2011;55:459-72.
  28. Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus.Dermatol Clin. 2003;21:311-20.
  29. Schlippe G, Voss W, Bayer M, et al. Neue Behandlungsmethode bei einem Herpes-labialis-Rezidiv. [New method of treatment for a herpes labialis recurrence].

AUTHOR CORRESPONDENCE

Ted Rosen MD vampireted@aol.com
Close Menu